a-j, Body weight (a), liver weight (b), fat weight (c), lean weight (d), fasting liver triglycerides (e), lipoprotein-associated serum cholesterol (f), liver cholesterol (g), serum non-esterified free fatty acids (NEFA) (h), liver NEFA (i) and serum insulin (j) levels, in control or TSC22D4 shRNA adenovirus-injected C57Bl6 mice 7 days after injection (means ± SEM, n≥7). k-l, Hepatic TSC22D4 RNA (k) and protein (l) levels in TSC22D4 miRNA adenoassociated virus-injected C57Bl6 mice (means ± SEM, n≥5). m -n, Serum triglyceride (m) and cholesterol (n) levels in the same mice as in k. Statistical test a-d, g-k, m-n: student's t-test.
Supplementary figure 4.
a-f, body weight (a), fat weight (b), lean weight (c), liver weight (d), serum cholesterol (e) and liver cholesterol (f) levels in fasted or fed control or TSC22D4 cDNA adenovirusinjected C57Bl6 mice 7 days after injection (means ± SEM, n ≥4). g -l, Hepatic TSC22D4 protein levels (g), body weight (h), fat weight (i), lean weight (j), serum cholesterol (k) and liver cholesterol (l) levels in control or TSC22D4 cDNA adenovirus-injected C57Bl6 mice fed either a low fat diet (LFD) or a high fat diet (HFD) for 11 weeks 7 days after injection (means ± SEM, n≥3). Statistical test a-f, h-l: student's t-test.
Supplementary figure 5.
a, Quantitative PCR analysis of lipolysis stimulated lipoprotein receptor (Lsr), low-density lipoprotein receptor (Ldlr) and lipoprotein receptor-related protein (Lrp) mRNA levels in livers of control or TSC22D4 shRNA-injected wild-type C57Bl6 mice (means ± SEM, n ≥ 7).
b, Quantitative PCR analysis of src-homology protein 1 (Shp1), cholesterol 7 alpha- 
